Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Immix Biopharma ( (IMMX) ).
Immix Biopharma, Inc. has updated its consents from KMJ Corbin & Company LLP and Crowe LLP, its former and current independent registered public accounting firms, respectively. These updates, dated November 26, 2025, pertain to the incorporation of their reports into the company’s Registration Statement, reflecting the consolidated financial statements for the year ended December 31, 2024.
The most recent analyst rating on (IMMX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Immix Biopharma stock, see the IMMX Stock Forecast page.
More about Immix Biopharma
Average Trading Volume: 529,369
Technical Sentiment Signal: Buy
Current Market Cap: $144.4M
For a thorough assessment of IMMX stock, go to TipRanks’ Stock Analysis page.